Lv4
488 积分 2024-08-27 加入
Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
1个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
2个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
2个月前
已完结
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy in Non-Small Cell Lung Cancer
3个月前
已完结
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
3个月前
已完结
AI in Peer Review
3个月前
已关闭
The mechanism of apatinib reprogramming arginine metabolism in cervical cancer to enhance the anti-tumor effect of anti-PD-1 immunotherapy
3个月前
已关闭
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): A prospective, single-arm, phase II trial
3个月前
已关闭
RJBLC-NEBC001: A prospective, single-arm study on neoadjuvant adebrelimab plus etoposide and cisplatin in neuroendocrine bladder carcinoma
3个月前
已关闭
皖公网安备34019202002308
